New
HealthMore in Health→
VG-3927 Advances as a TREM2-Targeting Alzheimer’s Candidate
Key Takeaways
- Nature Medicine reports that VG-3927 is a small-molecule TREM2 agonist for Alzheimer’s disease.
- The report cites preclinical analysis and phase 1 trial support for the candidate.
- Further clinical research is needed to establish patient benefit.
DE
DT Editorial Team··via nature.com